Diabetic GLP-1 Agonists (Weekly) — Prior Authorization Guideline
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization requirements for weekly GLP-1 receptor agonists for treatment of diabetes (products listed include Exenatide, Mounjaro, Trulicity, Ozempic) affecting CareOregon members on the referenced formulary.
No material clinical or coverage changes in this revision.
Coverage Criteria for Weekly GLP-1 Agonists
Initial Authorization
Covered when ALL of the following are met
Primary requirements
Pathway
- 2.1: ASCVD or CKD pathway: Both of the following: (1) Patient has ASCVD OR chronic kidney disease with eGFR 25-75 mL/min/1.73 m2 and UACR greater than 100 mg/g; AND (2) one of: trial and failure/contraindication/intolerance to an SGLT2 inhibitor OR both continued treatment with an SGLT2 inhibitor and HbA1c > 7%
- 2.2: Multiple oral therapy failure pathway: All of the following: trial and failure or contraindication to metformin; HbA1c > 7%; and a minimum 3-month trial and failure to TWO of: sulfonylurea (e.g., glipizide, glimepiride), pioglitazone, alogliptin, or an SGLT2 inhibitor (at maximum tolerated doses)
Prior authorization is required for some agents
Liraglutide and coadministration restrictions
Reauthorization
Covered when ALL of the following are met for reauthorization
Obstructive Sleep Apnea (OSA) indication / Reauthorization
Covered when ALL of the following are met
The requested medication must not be co‑administered with another GLP‑1 receptor agonist or a dual GIP/GLP‑1 agent (for example, Mounjaro). Additionally, a documented trial and failure or a contraindication to liraglutide is required before approval of the weekly GLP‑1 agent.
For reauthorization and certain continuation pathways, the policy requires at least one HbA1c obtained within the previous 6 months. If an HbA1c value is not provided, the plan will grant a one‑time 2‑month grace approval; subsequent requests lacking a recent HbA1c will be denied for failure to meet reauthorization requirements.
Clinical Parameters and Coding-related Criteria
Provider Actions, Documentation & Prior Authorization
Prior authorization required — weekly GLP‑1 agonists
Prior authorization is required for the listed weekly GLP‑1 receptor agonists. Standard approval length is 12 months.
Step therapy: required trials/failures or contraindications
Document trials and either failures or contraindications to required prior therapies before approval: metformin, specified oral agents, SGLT2 inhibitors, and liraglutide. For the multiple‑oral‑therapy pathway, two distinct 3‑month trials at maximum tolerated doses are required.
- Trial and failure or contraindication to metformin (required pathway option).
- For the multi‑oral pathway: trial and failure (minimum 3 months each) to TWO of: sulfonylurea (e.g., glipizide, glimepiride), pioglitazone, alogliptin, or an SGLT2 inhibitor.
- Trial and failure or contraindication to liraglutide is required (separate requirement).
- If using the ASCVD/CKD pathway: trial and failure/contraindication to an SGLT2 inhibitor OR continued SGLT2 therapy with HbA1c >7%.
Supporting clinical documentation for OSA indication
When OSA‑related criteria are claimed, submit medical records (e.g., chart notes) documenting inability to tolerate positive airway pressure therapy or documentation of reduced sleep‑related impairment as specified.
- For inability to tolerate PAP: submit chart notes documenting intolerance.
- For continuing OSA benefit: submit records documenting reduction in sleep‑related impairment and status of PAP therapy (continuing therapy if applicable).
Missing recent HbA1c — one‑time 2‑month grace for reauthorization
If no HbA1c is provided for reauthorization, a one‑time 2‑month approval may be granted; subsequent requests without a recent HbA1c (within 6 months) will be denied.
- At least one HbA1c must have been obtained in the previous 6 months for reauthorization.
- If HbA1c is not provided, approve only for 2 months one time; deny after the first grace authorization if A1c remains missing.
Definitions and Related Terms
Background
Glucagon‑like peptide‑1 (GLP‑1) receptor agonists are indicated as glucose‑lowering agents for type 2 diabetes and are considered in this guideline for patients who may also have cardiovascular or renal disease. The coverage criteria specify clinical prerequisites for weekly GLP‑1 therapy, including documented diagnosis of Type 2 Diabetes, required prior trials (for example, metformin and a trial of liraglutide unless contraindicated), and comorbidity‑driven pathways such as ASCVD or chronic kidney disease with specified eGFR and UACR thresholds. Prior authorization is required for the listed products with a standard approval length of 12 months, and supporting documentation (including recent HbA1c values) is required for initial and ongoing coverage.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.